Advertisement
Journal Home
Search for

Volume 81, Issue 1, Pages 57-61 (January 2010)


View previous. 11 of 19 View next.

Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on lipid metabolism during 1 year of conventional or extended-cycle use

Inka WiegratzaCorresponding Author Informationemail address, Skadi Stahlberga, Torsten Mantheya, Nicole Sängera, Katrin Mittmannb, Ernesta Palombo-Kinneb, Uwe Mellingerb, Evelyn Langeb, Herbert Kuhla

Received 4 May 2009; received in revised form 30 July 2009; accepted 30 July 2009. published online 14 September 2009.

Abstract 

Background

The effects of extended regimens of combined oral contraceptives (COC) on lipid parameters are largely unknown. The present study compared the effects of a COC containing 30 mcg ethinyl estradiol and 2 mg dienogest (EE/DNG) in conventional and extended-cycle regimen over 1 year.

Study Design

Lipid parameters were measured in 59 women treated with EE/DNG either conventionally (21+7 days) or in extended-cycle regimen (84+7 days). Blood samples were taken in a control cycle and at 3 and 12 months of treatment.

Results

The mean levels of total cholesterol, HDL cholesterol and HDL2 cholesterol underwent modest to moderate significant increases over time, while the significant increase in triglycerides and VLDL cholesterol was more pronounced with both regimens. LDL cholesterol decreased slightly in both regimen groups, whereas lipoprotein(a) was transiently decreased at 3 months only in the extended-cycle group. The changes reached a steady-state at latest at 3 months, but did not exceed the given normal ranges for any of the parameters. Notably, except for lipoprotein(a), the changes in mean lipid levels were not significantly different in the conventional and the extended-cycle regimen at 3 or 12 months of treatment.

Conclusion

Use of EE/DNG in conventional or extended-cycle regimen resulted in comparable changes of lipid parameters.

a Center of Obstetrics and Gynecology, University Hospital of Frankfurt, D-60590 Frankfurt, Germany

b Jenapharm GmbH & Co KG, D-07745 Jena, Germany

Corresponding Author InformationCorresponding author. Department of Obstetrics and Gynecology, J.W. Goethe University, D-60590 Frankfurt am Main, Germany. Tel.: +49 69 63015708.

 The study was financially supported by Jenapharm GmbH & Co KG (Jena, Germany).

PII: S0010-7824(09)00356-4

doi:10.1016/j.contraception.2009.07.011


View previous. 11 of 19 View next.

Advertisement